Controlled Ovarian Hyperstimulation (COH) With Sequential HPFSH & HMG Versus Rec-F.S.H Alone in ICSI Cycle
Launched by ALAA FOULI GABER EBRAHIM · Aug 31, 2020
Trial Information
Current as of May 09, 2025
Unknown status
Keywords
ClinConnect Summary
, the objective of the current study was to compare the efficacy of 2 different ovarian stimulation protocols, comprising hpFSH, HMG versus R-FSH on oocyte and embryo quality and IVF treatment outcome in patients undergoing IVF or intracytoplasmic sperm injection (ICSI)(4).
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • 1-Aged 20-35 yr, male factor, 2-Tubal or unexplained infertility, 3-regular menstruation cycle between 21 and 35 days, 4-Normal function of uterus according to hysterosalpingography, hysteroscopy or transvaginal ultrasonography, 5-Normal ovaries according to transvaginal ultrasonography during past 6 months prior to study and compatible with normal adnexa and 6-Normal ovarian anatomy, and serum FSH level less than 8 IU/l All women showed no recognizable endometriosis according to symptoms and clinical examination in transvaginal ultrasonography or diagnostic laparoscopy. 7-7-All women have a history of unexplained infertility 8-Normal ovulatory function and normal semen analysis according to the World Health Organization criteria .
- Exclusion Criteria:
- • Patients with other ovulation disorders such as hypo and hypergonadotropic, hypogonadism, hyperprolactinemia.
- • 2-Thyroid disorders. 3-Ovarian or adrenal neoplasms. 4-Cushing syndrome. 5-previous history of systemic diseases such as endocrine and metabolic disorders.
- • 6- Previous history of inappropriate ovarian response to stimulation with gonadotropins (poor responders).
- • 7-Prior history of more than 3 unsucce
About Alaa Fouli Gaber Ebrahim
Alaa Fouli Gaber Ebrahim is a dedicated clinical trial sponsor with a strong commitment to advancing medical research and improving patient outcomes. With extensive experience in the field, Ebrahim oversees the design, implementation, and management of clinical studies, ensuring adherence to regulatory standards and ethical guidelines. His focus on innovative methodologies and collaboration with multidisciplinary teams fosters the development of groundbreaking therapies. Ebrahim's leadership in clinical trials not only contributes to scientific knowledge but also aims to enhance the quality of life for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Minya, , Egypt
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials